

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**FORM 6-K**

**REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 AND 15d-16 UNDER  
THE SECURITIES EXCHANGE ACT OF 1934**

For the Month of April 2014

File No. 000-54598

**Stellar Biotechnologies Inc.**  
(Name of Registrant)

**332 E. Scott Street, Port Hueneme, CA 93041**  
(Address of Principal executive offices)

Indicate by check mark whether the Registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

FORM 20-F                       FORM 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

**SIGNATURE**

Pursuant to the requirements of the securities Exchange Act of 1934, the registrant has duly caused this Form 6-K to be signed on its behalf by the undersigned, thereunto duly authorized.

Stellar Biotechnologies, Inc.  
(Registrant)

Dated: 4/1/14

By: /s/ Kathi Niffenegger  
Kathi Niffenegger  
Chief Financial Officer

---

**Exhibits:**

[99.1](#) News Release Dated April 1, 2014

---

**Stellar Biotechnologies Presenting Today at 2014 TSX Venture 50® Spotlight Event**

**PORT HUENEME, CA, (April 1, 2014) -- Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX-V: KLH),** announced that the company is presenting today at the 2014 TSX Venture 50® Spotlight Event being held in Calgary, Canada.

Stellar was recently ranked as the top company across all five industry sectors of the 2014 TSX Venture 50®, an exclusive listing of the highest performing companies on the TSX Venture Exchange.

The TSX Venture 50® Spotlight event is attended by the TSX Venture 50® corporations, portfolio managers, analysts, and members of the investment community.

Frank Oakes, President and CEO of Stellar Biotechnologies, Inc., will provide an overview of the company's focus in the immunotherapy arena with its world-leading technology in Keyhole Limpet Hemocyanin (KLH) protein.

"Being ranked as a top company on the TSX Venture Exchange signals strong public market endorsement of Stellar's strategy and achievements," said Mr. Oakes. "We are focused on growth opportunities that will further strengthen our position and expand our growth potential."

Read about the 2014 TSX Venture 50®:

<http://www.tmxmoney.com/en/research/tsxventure50.html>

TSX Venture 50® is a trademark of TSX Inc. and is used under license.

**About Stellar Biotechnologies, Inc.**

Stellar Biotechnologies, Inc. (OTCQB: SBOTF) (TSX VENTURE: KLH) is the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, infectious diseases, and immune disorders) as well as a finished product for measuring immune status. Stellar Biotechnologies is unique in its proprietary methods, facilities, and KLH technology. We are committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies.

To receive regular updates, enter email at <http://stellarbiotechnologies.com/contact/>

Visit [www.StellarBiotech.com](http://www.StellarBiotech.com) and the KLH knowledge base [www.KLHSite.org](http://www.KLHSite.org).

**Contacts:**

Frank Oakes  
President and CEO  
Phone +1 (805) 488-2800  
[IR@stellarbiotech.com](mailto:IR@stellarbiotech.com)

Mark McPartland  
Vice President of Corporate Development and Communications  
Phone: +1 (805) 488-2800 ext. 103  
[markmcp@stellarbiotech.com](mailto:markmcp@stellarbiotech.com)  
[www.stellarbiotech.com](http://www.stellarbiotech.com)

**Forward Looking Statements**

There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of these releases.

---